Vaccine Schedule Analyzer | Dr. Anderson's Clinical Tools

Patient

Age (years)

Sex

MaleFemaleFemale, pregnant

Paste immunization history

Documented immunity (pre-filled from serology in the pasted text — override as needed)

Documented measles/mumps/rubella immunityDocumented varicella immunity or disease historyDocumented hepatitis A immunityDocumented hepatitis B immunity

Common risk conditions

diabetes mellituschronic heart or lung disease (incl. asthma)cigarette smokingsevere obesity (BMI ≥40)immunocompromised (excluding HIV)kidney failure, ESRD, or on dialysischronic liver diseasealcohol use disorderresides in a nursing homehealth care personneltravel to an endemic areaasplenia or persistent complement component deficiency

All other risk conditions & exposures (0 of 52 selected in total)

Pregnancy

pregnant

Immunocompromise

HIV, CD4 <15% or <200 cells/mm³HIV, CD4 ≥15% and ≥200 cells/mm³hematopoietic stem cell transplantsolid organ transplanthousehold contact of an immunocompromised personfamily history of altered immunocompetence

Asplenia / complement

complement inhibitor (eculizumab, ravulizumab)chronic hematologic condition (e.g. sickle cell disease, thalassemia)persistent complement component deficiency

Kidney & liver

on dialysis (hemodialysis or peritoneal)

Occupational & congregate living

first-year college student in residential housingmicrobiologist routinely exposed to N. meningitidismilitary recruitoccupational hepatitis A exposure (research lab or nonhuman primate work)

Behavioral & sexual health

men who have sex with meninjection or non-injection drug useexperiencing homelessnessincarceratedsexual exposure risk for hepatitis B (partner of HBsAg+, STI evaluation, non-monogamous, MSM)behavioral/exposure risk factor for mpox

Travel & exposure

close contact of an international adoptee from a hepatitis-A-endemic country

Vaccination history, allergy & precautions

cochlear implantcerebrospinal fluid leakencephalopathy within 7 days of a prior DTP/DTaP/Tdap dosesevere allergic reaction (e.g. anaphylaxis) to a previous dose or vaccine componentGuillain-Barre syndrome within 6 weeks of a prior influenza vaccineGuillain-Barre syndrome within 6 weeks of a prior tetanus-toxoid-containing vaccinehistory of Arthus-type hypersensitivity reaction to a tetanus- or diphtheria-toxoid-containing vaccinerecent (≤11 months) receipt of an antibody-containing blood productrecent antiviral use (acyclovir, famciclovir, or valacyclovir)aspirin or aspirin-containing product usecurrent episode of herpes zostermyocarditis or pericarditis after a prior COVID-19 vaccine doselatex sensitivitynot vaccinated in childhood, or raised outside the United States

Other medical

progressive or unstable neurological disorder, uncontrolled seizures, or progressive encephalopathyhistory of thrombocytopenia or thrombocytopenic purpuraneurologic/neuromuscular condition causing impaired airway clearance or respiratory muscle weaknesswound requiring tetanus prophylaxis assessment